318 related articles for article (PubMed ID: 25564255)
1. Nano-pharmaceutical formulations for targeted drug delivery against HER2 in breast cancer.
Sadat SM; Saeidnia S; Nazarali AJ; Haddadi A
Curr Cancer Drug Targets; 2015; 15(1):71-86. PubMed ID: 25564255
[TBL] [Abstract][Full Text] [Related]
2. Polymer-lipid hybrid anti-HER2 nanoparticles for targeted salinomycin delivery to HER2-positive breast cancer stem cells and cancer cells.
Li J; Xu W; Yuan X; Chen H; Song H; Wang B; Han J
Int J Nanomedicine; 2017; 12():6909-6921. PubMed ID: 29075110
[TBL] [Abstract][Full Text] [Related]
3. Lipid-based nanoparticulate delivery systems for HER2-positive breast cancer immunotherapy.
Behravan N; Zahedipour F; Jaafari MR; Johnston TP; Sahebkar A
Life Sci; 2022 Feb; 291():120294. PubMed ID: 34998838
[TBL] [Abstract][Full Text] [Related]
4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
5. Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin.
Farasat A; Rahbarizadeh F; Ahmadvand D; Ranjbar S; Khoshtinat Nikkhoi S
J Liposome Res; 2019 Mar; 29(1):53-65. PubMed ID: 29621912
[TBL] [Abstract][Full Text] [Related]
6. Nano-drug delivery system: a promising approach against breast cancer.
Malik JA; Ansari JA; Ahmed S; Khan A; Ahemad N; Anwar S
Ther Deliv; 2023 May; 14(5):357-381. PubMed ID: 37431741
[TBL] [Abstract][Full Text] [Related]
7. Drug delivery approaches for breast cancer.
Singh SK; Singh S; Lillard JW; Singh R
Int J Nanomedicine; 2017; 12():6205-6218. PubMed ID: 28883730
[TBL] [Abstract][Full Text] [Related]
8. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy.
Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM
Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810
[TBL] [Abstract][Full Text] [Related]
9. Investigation of an antitumor drug-delivery system based on anti-HER2 antibody-conjugated BSA nanoparticles.
Zhang N; Zhang J; Wang P; Liu X; Huo P; Xu Y; Chen W; Xu H; Tian Q
Anticancer Drugs; 2018 Apr; 29(4):307-322. PubMed ID: 29381491
[TBL] [Abstract][Full Text] [Related]
10. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
11. Development of anti-HER2-targeted doxorubicin-core-shell chitosan nanoparticles for the treatment of human breast cancer.
Naruphontjirakul P; Viravaidya-Pasuwat K
Int J Nanomedicine; 2019; 14():4105-4121. PubMed ID: 31239670
[No Abstract] [Full Text] [Related]
12. Evolution of anti-HER2 therapies for cancer treatment.
Parakh S; Gan HK; Parslow AC; Burvenich IJG; Burgess AW; Scott AM
Cancer Treat Rev; 2017 Sep; 59():1-21. PubMed ID: 28715775
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
14. Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.
Sempkowski M; Zhu C; Menzenski MZ; Kevrekidis IG; Bruchertseifer F; Morgenstern A; Sofou S
Langmuir; 2016 Aug; 32(33):8329-38. PubMed ID: 27468779
[TBL] [Abstract][Full Text] [Related]
15. Nanomedicines for active targeting: physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells.
Cirstoiu-Hapca A; Buchegger F; Bossy L; Kosinski M; Gurny R; Delie F
Eur J Pharm Sci; 2009 Oct; 38(3):230-7. PubMed ID: 19632322
[TBL] [Abstract][Full Text] [Related]
16. Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts.
Hoang B; Ekdawi SN; Reilly RM; Allen C
Mol Pharm; 2013 Nov; 10(11):4229-41. PubMed ID: 24066900
[TBL] [Abstract][Full Text] [Related]
17. Liposomal nanoparticle armed with bivalent bispecific single-domain antibodies, novel weapon in HER2 positive cancerous cell lines targeting.
Nikkhoi SK; Rahbarizadeh F; Ranjbar S; Khaleghi S; Farasat A
Mol Immunol; 2018 Apr; 96():98-109. PubMed ID: 29549861
[TBL] [Abstract][Full Text] [Related]
18. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
[TBL] [Abstract][Full Text] [Related]
19. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.
Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW
Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648
[TBL] [Abstract][Full Text] [Related]
20. A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy.
Guo Y; Wang XY; Chen YL; Liu FQ; Tan MX; Ao M; Yu JH; Ran HT; Wang ZX
Acta Biomater; 2018 Oct; 80():308-326. PubMed ID: 30240955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
